Logo

Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae

Share this

Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae

Shots:

  • The P-II clinical trial involves evaluating ASP377 (a novel 24 valent MAPS Vaccine) vs Prevnar 13 & Pneumovax 23 in 503 adults aged 65-85yrs. with Streptococcus pneumoniae. The vaccine was developed using Affinivax’s MAPS platform technology
  • The results showed that the ASP3772 was well tolerated- induced a robust immune response in 24 pneumococcal serotypes in MAPS vaccine as measured by IgG & OPA & showed an increase in Abs response to the conserved pneumococcal proteins
  • ASP3772 has also received FDA’s BTD in adults aged >50 yrs. for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes- based on P-II results

  Ref: Astellas | Image: Financial Times

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions